Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens

被引：32

作者：

Dorrucci, M

Pezzotti, P

Grisorio, B

Minardi, C

Muro, MS

Vullo, V

Monforte, AD

机构：

[1] Ist Super Sanita, Reparto AIDS MST, I-00161 Rome, Italy

[2] Osped Riuniti Foggia, Dept Infect Dis, Foggia, Italy

[3] Univ Brescia, Inst Infect & Trop Dis, Brescia, Italy

[4] Univ Sassari, Inst Infect Dis, I-07100 Sassari, Italy

[5] Univ Roma La Sapienza, Inst Infect Dis, Rome, Italy

[6] Univ Milan, Inst Infect & Trop Dis, Milan, Italy

来源：

AIDS | 2001年 / 15卷 / 13期

关键词：

D O I：

10.1097/00002030-200109070-00020

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Data from a cohort of HIV-positive individuals who were antiretroviral naive at enrolment were analysed to estimate the probability of discontinuing the first highly active antiretroviral therapy (HAART) regimen, comparing protease inhibitor and non-nucleoside reverse transcriptase- containing regimens. Of the 2002 individuals who began HAART, 857 (42.8%) discontinued their first regimen. No statistically significant difference was found in the time to discontinuation by specific type of regimen, either when considered overall or by specific reason.

引用

页码：1733 / 1736

页数：4

共 10 条

[1] Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].

Cameron, DW ;

Heath-Chiozzi, M ;

Danner, S ;

Cohen, C ;

Kravcik, S ;

Maurath, C ;

Sun, E ;

Henry, D ;

Rode, R ;

Potthoff, A ;

Leonard, J .

LANCET, 1998, 351 (9102) :543-549

[2]

DARMINIO MA, 1998, AIDS, V12, P1631

[3] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].

Hammer, SM ;

Squires, KE ;

Hughes, MD ;

Grimes, JM ;

Demeter, LM ;

Currier, JS ;

Eron, JJ ;

Feinberg, JE ;

Balfour, HH ;

Dayton, LR ;

Chodakewitz, JA ;

Fischl, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733

[4] Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre [J].

Mocroft, A ;

Youle, M ;

Moore, A ;

Sabin, CA ;

Madge, S ;

Lepri, AC ;

Tyrer, M ;

Chaloner, C ;

Wilson, D ;

Loveday, C ;

Johnson, MA ;

Phillips, AN .

AIDS, 2001, 15 (02) :185-194

[5] Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients [J].

Monforte, AD ;

Lepri, AC ;

Rezza, G ;

Pezzotti, P ;

Antinori, A ;

Phillips, AN ;

Angarano, G ;

Colangeli, V ;

De Luca, A ;

Ippolito, G ;

Caggese, L ;

Soscia, F ;

Filice, G ;

Gritti, F ;

Narciso, P ;

Tirelli, U ;

Moroni, M .

AIDS, 2000, 14 (05) :499-507

[6]

MONFORTE AD, 1998, AIDS, V12, pP99

[7] Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults [J].

Staszewski, S ;

Morales-Ramirez, J ;

Tashima, KT ;

Rachlis, A ;

Skiest, D ;

Stanford, J ;

Stryker, R ;

Johnson, P ;

Labriola, DF ;

Farina, D ;

Manion, DJ ;

Ruiz, NM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1865-1873

[8] Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants [J].

van Roon, EN ;

Verzijl, JM ;

Juttmann, JR ;

Lenderink, AW ;

Blans, MJ ;

Egberts, ACG .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (03) :290-294

[9]

Youle M, 1998, AIDS, V12, pS63

[10]

1992, MMWR, V41, P19

← 1 →